Adrenal Cancer
Welcome,         Profile    Billing    Logout  
 2 Companies   1 Product   1 Product   14 Mechanisms of Action   0 Trials   14 News 
  • ||||||||||  Biomarker, Trial termination:  Evaluation of Molecular Markers in Adrenal Tumors (clinicaltrials.gov) -  Jan 17, 2018   
    P=N/A,  N=74, Terminated, 
    Completed --> Terminated; Slow/insufficient accrual
  • ||||||||||  Biomarker, Trial completion, Enrollment change:  Evaluation of Molecular Markers in Adrenal Tumors (clinicaltrials.gov) -  Dec 7, 2017   
    P=N/A,  N=71, Completed, 
    Completed --> Terminated; Slow/insufficient accrual Recruiting --> Completed | N=500 --> 71
  • ||||||||||  nevanimibe (ATR-101) / Millendo Therap
    Trial completion, Trial primary completion date, Metastases:  Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) -  Nov 6, 2017   
    P1,  N=63, Completed, 
    Recruiting --> Completed | N=500 --> 71 Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Nov 2016
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, Metastases:  Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer (clinicaltrials.gov) -  Sep 29, 2017   
    P2,  N=6, Terminated, 
    Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Nov 2016 N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment
  • ||||||||||  nevanimibe (ATR-101) / Millendo Therap
    Trial primary completion date, Metastases:  Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) -  Feb 7, 2017   
    P1,  N=78, Recruiting, 
    N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment Trial primary completion date: Feb 2017 --> Feb 2019
  • ||||||||||  nevanimibe (ATR-101) / Millendo Therap
    Enrollment change, Trial primary completion date, Metastases:  Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) -  Feb 17, 2016   
    P1,  N=78, Recruiting, 
    Trial primary completion date: Feb 2017 --> Feb 2019 N=59 --> 78 | Trial primary completion date: Dec 2015 --> Feb 2017
  • ||||||||||  nevanimibe (ATR-101) / Millendo Therap
    Trial primary completion date, Metastases:  Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) -  Jun 11, 2015   
    P1,  N=59, Recruiting, 
    N=59 --> 78 | Trial primary completion date: Dec 2015 --> Feb 2017 Trial primary completion date: Jun 2015 --> Dec 2015
  • ||||||||||  Enrollment change, Trial primary completion date, Metastases:  Possible New Therapy for Advanced Cancer (clinicaltrials.gov) -  Nov 19, 2014   
    P1/2,  N=9, Terminated, 
    Trial primary completion date: Jun 2015 --> Dec 2015 N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014
  • ||||||||||  Trial termination, Metastases:  Possible New Therapy for Advanced Cancer (clinicaltrials.gov) -  Nov 18, 2014   
    P1/2,  N=36, Terminated, 
    N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014 Recruiting --> Terminated; Business decision by the sponsor during Phase 1.
  • ||||||||||  nevanimibe (ATR-101) / Millendo Therap
    Enrollment change, Trial primary completion date, Metastases:  Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) -  Aug 21, 2014   
    P1,  N=59, Recruiting, 
    Recruiting --> Terminated; Business decision by the sponsor during Phase 1. N=21 --> 59 | Trial primary completion date: Aug 2014 --> Jun 2015